Whitehawk Therapeutics (WHWK) Free Cash Flow (2010 - 2026)

Whitehawk Therapeutics (WHWK) has reported Free Cash Flow for 17 consecutive years, with -$22.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 89.0% year-over-year to -$22.2 million; the TTM figure through Mar 2026 stood at -$107.9 million (down 101.9% YoY), while the FY2025 annual figure was -$97.4 million, down 59.19% from the prior year.
• Free Cash Flow retreated to -$22.2 million in Q1 2026 per WHWK's latest filing, from -$17.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$8.0 million in Q3 2022 and bottomed at -$53.6 million in Q2 2025.
• Historically, Free Cash Flow has averaged -$17.1 million across 5 years, with a median of -$14.8 million in 2025.
• Annual changes were most pronounced in 2022 — Free Cash Flow soared 54.0% — and 2025, when it plunged 407.07%.
• Whitehawk Therapeutics' Free Cash Flow stood at -$11.7 million in 2022, then advanced by 18.56% to -$9.5 million in 2023, then slumped by 79.27% to -$17.1 million in 2024, then fell by 0.94% to -$17.2 million in 2025, then dropped by 28.86% to -$22.2 million in 2026.
• Business Quant data shows WHWK's Free Cash Flow at -$22.2 million in Q1 2026, -$17.2 million in Q4 2025, and -$14.8 million in Q3 2025.